KRAS and neoplasm: Indeed, the abundance of the targeted KRAS G12V peptide/HLA complex on the surface of in vitro–cultured tumor cells in this study was variable, often between four and 242 copies per cell even in cell lines that were engineered to constitutively express the restricting HLA molecule.